Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 2/20 | 0.39 |
| ▸ | METAP1 | P53582 | 2/20 | 0.39 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.39 |
| ▸ | G6PD | P11413 | 1/20 | 0.39 |
| ▸ | NFKBIA | P25963 | 1/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1778896 | 0.88 | L3MBTL1 (0.55) | CYP2C19ALDH1A1LMNAMAPTPTGDR2 | |
| SCHEMBL13596799 | 0.88 | CYP2C19 (0.51) | CYP2C19RECQLALDH1A1LMNAMAPT | |
| SCHEMBL21295075 | 0.82 | MET (0.40) | CYP2C19RECQLALDH1A1LMNAMAPT | |
| SCHEMBL29847060 | 0.82 | MET (0.40) | CYP2C19RECQLALDH1A1LMNAMAPT | |
| SCHEMBL30337641 | 0.81 | CYP2C19 (0.56) | CYP2C19RECQLALDH1A1LMNAMAPT | |
| SCHEMBL1772416 | 0.81 | CYP2C19 (0.56) | CYP2C19RECQLALDH1A1LMNAMAPT | |
| SCHEMBL1773438 | 0.80 | CYP2C19 (0.55) | CYP2C19RECQLALDH1A1LMNAMAPT | |
| SCHEMBL28497684 | 0.80 | CYP2C19 (0.55) | CYP2C19RECQLALDH1A1LMNAMAPT | |
| SCHEMBL30559878 | 0.80 | CYP2C19 (0.55) | CYP2C19RECQLALDH1A1LMNAMAPT | |
| SCHEMBL2590156 | 0.80 | CYP2C19 (0.55) | CYP2C19RECQLALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110194770-B | Peptidyl arginine deiminase inhibitors and uses thereof | 药捷安康(南京)科技股份有限公司 | 2022-08-09 | — | — | CN | disclosed |
| EP-3760628-A1 | PEPTIDYLARGININE DEIMINASE INHIBITOR AND USE THEREOF | Nanjing Transthera Biosciences Co., Ltd. (CN) | 2021-01-06 | — | — | EP | disclosed |
| EP-3760628-A1 | PEPTIDYLARGININE DEIMINASE INHIBITOR AND USE THEREOF | Nanjing Transthera Biosciences Co., Ltd. (CN) | 2021-01-06 | — | — | EP | disclosed |
| US-20200407370-A1 | PEPTIDYLARGININE DEIMINASE INHIBITOR AND USE THEREOF | NANJING TRANSTHERA BIOSCIENCES CO., LTD. (CN) | 2020-12-31 | — | — | US | disclosed |
| US-20200407370-A1 | PEPTIDYLARGININE DEIMINASE INHIBITOR AND USE THEREOF | NANJING TRANSTHERA BIOSCIENCES CO., LTD. (CN) | 2020-12-31 | — | — | US | disclosed |
| CN-110194770-A | Peptide acyl arginine deiminase inhibitor and application thereof | 南京药捷安康生物科技有限公司 | 2019-09-03 | — | — | CN | disclosed |
| WO-2019161803-A1 | PEPTIDYLARGININE DEIMINASE INHIBITOR AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2019-08-29 | — | — | WO | disclosed |
| WO-2019161803-A1 | PEPTIDYLARGININE DEIMINASE INHIBITOR AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2019-08-29 | — | — | WO | disclosed |
| US-10039755-B2 | 2-(azaindol-2-yl) benzimidazoles as PAD4 inhibitors | GLAXO GROUP LIMITED (GB) | 2018-08-07 | — | — | US | disclosed |
| US-10039755-B2 | 2-(azaindol-2-yl) benzimidazoles as PAD4 inhibitors | GLAXO GROUP LIMITED (GB) | 2018-08-07 | — | — | US | disclosed |
| US-20150175600-A1 | 2-(AZAINDOL-2-YL)BENZIMIDAZOLES AS PAD4 INHIBITORS | Glaxo Group Limited a corporation | 2015-06-25 | — | — | US | disclosed |
| US-20150175600-A1 | 2-(AZAINDOL-2-YL)BENZIMIDAZOLES AS PAD4 INHIBITORS | Glaxo Group Limited a corporation | 2015-06-25 | — | — | US | disclosed |
| US-20150175600-A1 | 2-(AZAINDOL-2-YL)BENZIMIDAZOLES AS PAD4 INHIBITORS | Glaxo Group Limited a corporation | 2015-06-25 | — | — | US | disclosed |
| US-8338452-B2 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20110110889-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Bio Pharma Inc. (US) | 2011-05-12 | — | — | US | disclosed |
| EP-2265608-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009111278-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20070299091-A1 | Azaindole Carboxamides | GMEINER PETER | 2007-12-27 | — | — | US | disclosed |
| EP-1771448-A1 | AZAINDOLE CARBOXAMIDES | SCHWARZ PHARMA AG (DE) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006050976-A1 | AZAINDOLE CARBOXAMIDES | SCHWARZ PHARMA AG (DE) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299091-A1 | Azaindole Carboxamides | TPH1, TPH2, HTR1A | CYP2C19 400/4885RECQL 2476/4885ALDH1A1 505/4885 |
| US-10039755-B2 | 2-(azaindol-2-yl) benzimidazoles as PAD4 inhibitors | PADI1, PADI4, PADI2 | CYP2C19 478/4885RECQL 476/4885ALDH1A1 98/4885 |
| US-20200407370-A1 | PEPTIDYLARGININE DEIMINASE INHIBITOR AND USE THEREOF | PADI4, PADI2, PADI1 | CYP2C19 703/4885RECQL 898/4885ALDH1A1 2839/4885 |
| US-20150175600-A1 | 2-(AZAINDOL-2-YL)BENZIMIDAZOLES AS PAD4 INHIBITORS | PADI1, PADI4, PADI2 | CYP2C19 439/4885RECQL 390/4885ALDH1A1 77/4885 |
| US-20110110889-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | CYP2C19 2418/4885RECQL 2120/4885ALDH1A1 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.